ER-100 Human Trial: What Partial Reprogramming Does Not Yet Prove

Reviewed August 27, 2026. We checked the current ClinicalTrials.gov record, the sponsor’s first-dose announcement, the foundational mouse paper, and FDA gene-therapy requirements. ER-100 was recruiting in a small Phase 1 eye-disease study. It was not an approved longevity treatment.

Short answer: ER-100 is an investigational gene therapy designed to activate three reprogramming factors in retinal cells. Its first human study is testing safety and tolerability in people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy. The trial does not test whole-body rejuvenation, general longevity, or a consumer biological-age service.¹

The first participant was dosed in June 2026, according to the sponsor.² That is a genuine translational milestone. It means a regulated human experiment has begun. It does not mean partial epigenetic reprogramming has reversed aging in a person.

Trial facts, without the marketing layer

Field	Current registry information
Registry	NCT07290244
Phase	Phase 1
Status on August 27, 2026	Recruiting
Estimated enrollment	18 participants
Conditions	Open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy
Delivery	One intravitreal injection into one eye
Activation	Systemic doxycycline for 56 days
Sponsor	Life Biosciences
Actual study start	March 2, 2026

ClinicalTrials.gov listed four recruiting locations in the United States when we reviewed the record.¹ Trial status can change, so prospective participants should rely on the registry and study contacts rather than a clinic, news article, or social post.

The sponsor reported that the first participant was dosed on June 9, 2026. It described safety and tolerability as the primary focus, with additional measures of visual function.² Sponsor announcements are useful for milestones, but the registry is the authoritative source for recruitment status and protocol details.

What ER-100 is trying to do

ER-100 uses an adeno-associated viral vector delivered into the eye. The construct is designed to express OCT4, SOX2, and KLF4, often shortened to OSK. Doxycycline acts as a control switch for a limited activation period.

These factors are associated with cellular reprogramming. Full reprogramming can erase cell identity and carries major safety concerns. The partial approach aims to change some age-associated cellular state while preserving the cell’s specialized role.

The scientific precedent comes from a 2020 mouse study. Researchers used OSK expression in retinal ganglion cells and reported recovery of youthful gene-expression patterns, axon regeneration, and improved visual function in mouse models of optic nerve injury and glaucoma.³ That work supports a rationale for an eye trial. It is still mouse evidence, not proof of benefit in humans.

What first dosing means

First dosing establishes four narrow facts:

• a regulator allowed the investigational study to proceed;
• a trial site enrolled and treated at least one eligible participant;
• the manufacturing, delivery, and monitoring process reached clinical use;
• human safety data can now begin to accumulate.

It does not establish:

• clinical efficacy;
• reversal of a person’s biological age;
• safety outside the eye;
• durability beyond the trial’s follow-up;
• suitability for healthy adults;
• availability through longevity clinics.

In the United States, an investigational gene-therapy study requires an active investigational new drug application. Marketing a biological product requires FDA approval through a biologics license application.⁴ Permission to run a trial and approval to sell a treatment are different regulatory states.

Why the eye is not the whole body

The eye offers local delivery, measurable structure and function, and a defined disease context. Those features make it a more controlled starting point than systemic treatment.

Whole-body reprogramming would raise substantially broader questions:

• Can expression be controlled equally across organs?
• What happens if some cells lose identity?
• Could altered growth programs increase tumor risk?
• How would immune reactions to the vector be managed?
• Can the treatment be stopped or reversed?
• Would changes in an epigenetic clock correspond to better health or function?

A favorable eye-safety result would not answer those questions. Even a visual benefit would validate a disease-specific ocular application before it validated a general longevity claim.

Reprogramming is not an epigenetic clock

The terms are often mixed in clinic marketing:

• Epigenetic clocks estimate age-related patterns in DNA methylation. They are measurement models.
• Partial epigenetic reprogramming is an intervention intended to alter cellular state.
• Clinical rejuvenation would require evidence that people function better, experience less disease, or live longer with acceptable risk.

Changing a measurement does not automatically improve health. Likewise, testing a reprogramming intervention does not make every commercial “cellular reset” product scientifically related to ER-100.

A claim-check for patients and investors

If a provider uses ER-100 to promote a service, ask:

1. Is the service the exact ER-100 product in NCT07290244?
2. Is the patient enrolled through an official study site?
3. Which disease and clinical endpoint is being treated?
4. What evidence connects the provider’s product to OSK expression, dose control, and trial manufacturing?
5. Is the claim about eye safety, visual function, a biomarker, or whole-body aging?
6. Has any result been published, or is the claim based only on first dosing?

An answer that jumps from “a participant was treated” to “age reversal is here” omits every efficacy and safety step in between.

What evidence would change the conclusion?

The next meaningful evidence will be:

1. transparent adverse-event and dose data from the Phase 1 study;
2. evidence that OSK activation is controllable in human retinal tissue;
3. a credible visual-function or structural signal;
4. durability after doxycycline activation ends;
5. larger controlled studies in a defined eye condition;
6. independent replication and longer follow-up.

Only after disease-specific safety and benefit are established would broader applications become a serious clinical question. Systemic longevity use would require its own preclinical package and human trials.

Bottom line

ER-100 marks the start of human testing for one controlled, local partial-reprogramming strategy. The appropriate interpretation is Phase 1 ocular gene-therapy research, not human age reversal.

For clinic buyers, the practical rule is simple: do not pay for “epigenetic reprogramming” on the strength of a first-dose announcement. Verify the exact product, registry, indication, study site, and human results.

Footnotes

1. ClinicalTrials.gov. NCT07290244, record reviewed August 27, 2026. ↩ ↩²

2. Life Biosciences. First patient dosed in Phase 1 trial of ER-100 for optic neuropathies, June 2026. ↩ ↩²

3. Lu Y, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588:124-129. ↩

4. U.S. Food and Drug Administration. What is Gene Therapy?, accessed August 27, 2026. ↩